CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma

Medicine & Life Sciences

• 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 100%
• Receptor, Fibroblast Growth Factor, Type 3 83%
• Multiple Myeloma 53%
• Protein-Tyrosine Kinases 49%
• Mouse Fgfr3 protein 16%
• Cell Line 9%
• Mitogen-Activated Protein Kinase 3 9%
• Therapeutics 8%
• Cytostatic Agents 8%
• Mitogen-Activated Protein Kinase 1 8%
• Ectopic Gene Expression 8%
• Receptor Protein-Tyrosine Kinases 8%
• Coculture Techniques 7%
• Inhibitory Concentration 50 7%
• Heterografts 6%
• Intercellular Signaling Peptides and Proteins 6%
• Phosphotransferases 6%
• Interleukin-6 6%
• Clinical Studies 5%
• Phosphorylation 5%
• Insulin 5%
• Apoptosis 4%
• Growth 3%
• In Vitro Techniques 3%

Chemical Compounds

• Tyrosine Kinase Inhibitor 76%
• Inhibitory Concentration 8%
• Growth Factor 8%
• Insulin Derivative 6%
• Tyrosine 6%
• Resistance 4%